Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons
Asthma is a prevalent chronic non-communicable disease, affecting approximately 300 million people worldwide. It is characterized by significant airway inflammation, hyperresponsiveness, obstruction, and remodeling. Eosinophilic asthma, a subtype of asthma, involves the accumulation of eosinophils i...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/13/5/384 |
| _version_ | 1797264747543920640 |
|---|---|
| author | Musaddique Hussain Gang Liu |
| author_facet | Musaddique Hussain Gang Liu |
| author_sort | Musaddique Hussain |
| collection | DOAJ |
| description | Asthma is a prevalent chronic non-communicable disease, affecting approximately 300 million people worldwide. It is characterized by significant airway inflammation, hyperresponsiveness, obstruction, and remodeling. Eosinophilic asthma, a subtype of asthma, involves the accumulation of eosinophils in the airways. These eosinophils release mediators and cytokines, contributing to severe airway inflammation and tissue damage. Emerging evidence suggests that targeting eosinophils could reduce airway remodeling and slow the progression of asthma. To achieve this, it is essential to understand the immunopathology of asthma, identify specific eosinophil-associated biomarkers, and categorize patients more accurately based on the clinical characteristics (phenotypes) and underlying pathobiological mechanisms (endotypes). This review delves into the role of eosinophils in exacerbating severe asthma, exploring various phenotypes and endotypes, as well as biomarkers. It also examines the current and emerging biological agents that target eosinophils in eosinophilic asthma. By focusing on these aspects, both researchers and clinicians can advance the development of targeted therapies to combat eosinophilic pathology in severe asthma. |
| first_indexed | 2024-04-25T00:33:49Z |
| format | Article |
| id | doaj.art-d984083402cc495cb5b799d3f070dd56 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-04-25T00:33:49Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-d984083402cc495cb5b799d3f070dd562024-03-12T16:41:31ZengMDPI AGCells2073-44092024-02-0113538410.3390/cells13050384Eosinophilic Asthma: Pathophysiology and Therapeutic HorizonsMusaddique Hussain0Gang Liu1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USADivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USAAsthma is a prevalent chronic non-communicable disease, affecting approximately 300 million people worldwide. It is characterized by significant airway inflammation, hyperresponsiveness, obstruction, and remodeling. Eosinophilic asthma, a subtype of asthma, involves the accumulation of eosinophils in the airways. These eosinophils release mediators and cytokines, contributing to severe airway inflammation and tissue damage. Emerging evidence suggests that targeting eosinophils could reduce airway remodeling and slow the progression of asthma. To achieve this, it is essential to understand the immunopathology of asthma, identify specific eosinophil-associated biomarkers, and categorize patients more accurately based on the clinical characteristics (phenotypes) and underlying pathobiological mechanisms (endotypes). This review delves into the role of eosinophils in exacerbating severe asthma, exploring various phenotypes and endotypes, as well as biomarkers. It also examines the current and emerging biological agents that target eosinophils in eosinophilic asthma. By focusing on these aspects, both researchers and clinicians can advance the development of targeted therapies to combat eosinophilic pathology in severe asthma.https://www.mdpi.com/2073-4409/13/5/384asthmaeosinophileosinophilic asthmabiomarkersinflammationinterleukins |
| spellingShingle | Musaddique Hussain Gang Liu Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons Cells asthma eosinophil eosinophilic asthma biomarkers inflammation interleukins |
| title | Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons |
| title_full | Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons |
| title_fullStr | Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons |
| title_full_unstemmed | Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons |
| title_short | Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons |
| title_sort | eosinophilic asthma pathophysiology and therapeutic horizons |
| topic | asthma eosinophil eosinophilic asthma biomarkers inflammation interleukins |
| url | https://www.mdpi.com/2073-4409/13/5/384 |
| work_keys_str_mv | AT musaddiquehussain eosinophilicasthmapathophysiologyandtherapeutichorizons AT gangliu eosinophilicasthmapathophysiologyandtherapeutichorizons |